Dr. Jin Leigang
金雷鋼

Biography

Dr. Jin’s research focuses on elucidating the biological functions and molecular mechanisms of endocrine fibroblast growth factors (FGFs) in metabolic homeostasis and cardiometabolic diseases by integrating molecular biology, structural biology, clinical investigation, and artificial intelligence (AI). One major research direction is the investigation of the FGF21/β-Klotho signaling axis in metabolic and cardiovascular diseases. His research has demonstrated that physical exercise enhances FGF21 sensitivity under metabolic stress, providing new mechanistic insights into the cardiometabolic benefits of exercise. Building on these findings, he is developing FGF21-based dual agonists for the treatment of obesity-related metabolic diseases.

Another research focus is the FGF23/Klotho signaling pathway in metabolic kidney-bone-cardiovascular disorders. His work aims to elucidate the mechanisms underlying FGF23 dysregulation and applies AI-assisted structure-guided drug design and high-throughput screening to develop long-acting peptide therapeutics and monoclonal antibodies targeting FGF23-related diseases. In parallel, Dr. Jin employs AI-assisted analyses of large-scale human cohorts, integrating proteomics, metabolomics, and multi-omics datasets to identify novel exercise-responsive factors and regulators of cardiometabolic diseases. He combines computational prediction with mechanistic validation and therapeutic development to accelerate the translation of biological discoveries into innovative therapeutic strategies.

Overall, Dr. Jin's research seeks to integrate endocrine biology, AI, and translational medicine to uncover fundamental mechanisms of metabolic homeostasis and develop next-generation biologics for cardiometabolic diseases.